Slide 1

Sanofi mission statement is to

provide potentially life-changing
treatments and the protection of
life-saving vaccines to millions
of people, and affordable access
to it’s medicines in some of the
world’s poorest countries.

Bargaining power of supplier Slide 2

Sanofi buys it’s raw material
from numerous suppliers, in
addition to Sanofi created
EUROAPI for API
manufacturing.
.
Threat of new entrants
New entrants in Drug
Manufacturers - Major brings
innovation, and put pressure on
Sanofi through lower pricing
strategy, reducing  costs, and
providing new value propositions
to the Customers.
Bargaining power of buyer
Sanofi supplies to 128 countries
(hospitals, Distributers, public
organizations, pharmacist).
Threat of substitutes

Sanofi has 91
projects in
clinical
development
34 of these
projects in
phase 3 or
submitted to
regulatory
authorities for
approval.
Pipeline highlights: 7 positive
pivotal read-out. 10 new
molecules. 5 basket studies. 8
major approval.
Rivalry
Sanofi faces intense competition
from both local and multinational
companies. Some of these
competitors include AstraZeneca
(AZN), Regeneron
Pharmaceuticals (REGN),
Vertex(VRTX), Bristol-Myers
Squibb (BMY) and many more
all of whom are competing for a
share of the pharmaceutical
market.
-

* Sanofi has three operating Slide 3

segments: Pharmaceuticals,
Vaccines, and Consumer
Healthcare. The
Pharmaceuticals segment
comprises, for all
geographical territories, the
commercial operations of
the following global
franchises: Specialty Care
(Dupixent® , Neurology &
Immunology, Rare
Diseases, Oncology, and
Rare Blood Disorders) and
General Medicines (Core
Assets and Non-Core
 Assets), together with
research, development and
production activities
dedicated to the
Pharmaceuticals segment.
This segment also includes
associates whose activities
are related to
pharmaceuticals. The
Vaccines segment
comprises, for all
geographical territories, the
commercial operations of
Sanofi Pasteur, together
with research, development
and production activities
dedicated to vaccines. The
Consumer Healthcare
segment comprises, for all
geographical territories, the
commercial operations for
Sanofi’s Consumer
Healthcare products,
together with research,
development and
production activities
dedicated to those products.

* Sanofi Manufacturing Slide 4

System, which is based
on major regional
manufacturing hubs
that make products
primarily for their
region while having the
capacity to supply other
regions. Combined with
a common culture of
industrial excellence.
* The entire industrial
network continues its
digital transformation
to ensure agility, higher
productivity, efficiency
and sustainable
 manufacturing.
* In addition, Sanofi
created EUROAPI, a
new European company
for the development,
production and
marketing of active
pharmaceutical
ingredients (APIs).

* Access to Slide 5

healthcare
Innovation
Patient safety
* Contribute to
WHO
partnership to
fight neglected
tropical
diseases.
* Invested in
R&D to fight
malaria,
tuberculosis and
lashmania.
* Plans to remove
all plastic blister
packs for its
syringe vaccines
by 2027. In
addition,
 committed to
eco-designing
all new products
by 2025. To
reduce
greenhouse gas
emissions by
55% by 2030,
all Sanofi sites
will use 100%
electricity from
renewable
sources and
have also set a
target of carbon
neutrality for car
fleet, both by
2030.
* Ensuring that
under-
represented
employees have
an equal chance
to succeed by
focusing on
access to
opportunities
and addressing
their specific
needs